Genomes and Genes
Affiliation: University of California
- Valera E, Mante M, Anderson S, Rockenstein E, Masliah E. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation. 2015;12:93 pubmed publisher..These results support the therapeutic potential of lenalidomide for reducing maladaptive neuroinflammation in PD and related neuropathologies. ..
- Spencer B, Potkar R, Metcalf J, Thrin I, Adame A, Rockenstein E, et al. Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem. 2016;291:1905-20 pubmed publisher..Overall, increased delivery of NPY to the CNS for AD might be an effective therapy especially if combined with an anti-AÎ² therapeutic. ..
- Fields J, OVERK C, Adame A, Florio J, Mante M, Pineda A, et al. Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. J Neuroinflammation. 2016;13:120 pubmed publisher..Together, these results suggest that FK506 might be potentially neuroprotective in patients with HAND by mitigating inflammation and mitochondrial alterations. ..
- Gillman A, Lee J, Ramachandran S, Capone R, Gonzalez T, Wrasidlo W, et al. Small molecule NPT-440-1 inhibits ionic flux through A?1-42 pores: Implications for Alzheimer's disease therapeutics. Nanomedicine. 2016;12:2331-2340 pubmed publisher..Combined with previous studies on site-specific amino acid substitutions, these results suggest that pharmacological modulation of A?1-42 could prevent amyloid pore-mediated AD pathogenesis. ..
- Wrasidlo W, Tsigelny I, Price D, Dutta G, Rockenstein E, Schwarz T, et al. A de novo compound targeting ?-synuclein improves deficits in models of Parkinson's disease. Brain. 2016;139:3217-3236 pubmed
- Kim C, Rockenstein E, Spencer B, Kim H, Adame A, Trejo M, et al. Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep. 2015;13:771-782 pubmed publisher..These results uncover roles of TLR2 in regulating neuronal autophagy and suggest that the TLR2 pathway may be targeted for autophagy activation strategies in treating neurodegenerative disorders. ..
- FIELDS J, Serger E, Campos S, Divakaruni A, Kim C, SMITH K, et al. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiol Dis. 2016;86:154-69 pubmed publisher..Promoting mitochondrial fission during HIV infection of the CNS may restore mitochondrial biogenesis and prevent neurodegeneration. ..
- Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, et al. Î±-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet. 2016;25:1100-15 pubmed publisher..Better understanding of the mechanisms of intracellular trafficking of Î±-syn might be important for understanding the pathogenesis and developing new treatments for synucleinopathies. ..
- Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129-31 pubmed..This case illustrates the effects of an Abeta-based immunization on AD pathogenesis in the absence of overt meningoencephalitis and leukoencephalopathy. ..
- Valera E, Spencer B, Fields J, Trinh I, Adame A, Mante M, et al. Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun. 2017;5:2 pubmed publisher..These results suggest that a strategic combination of treatments may improve the therapeutic outcome in trials for MSA and related neurodegenerative disorders. ..
- Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265-9 pubmed..These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions. ..
- Dhungel N, Eleuteri S, Li L, Kramer N, Chartron J, Spencer B, et al. Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on Î±-synuclein. Neuron. 2015;85:76-87 pubmed publisher..Finally, we provide a resource of candidate PD genes for future interrogation. ..
- Buxbaum J, Roberts A, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. Neuroscience. 2014;275:352-64 pubmed publisher..This is the first description of behavioral abnormalities in Rbp4(-/-)mice. The data also indicate that it is unlikely that the behaviors seen in Ttr(-/-) mice are related to its function as an RBP carrier. ..
- Fields J, Metcalf J, OVERK C, Adame A, Spencer B, Wrasidlo W, et al. The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. J Neurovirol. 2017;23:290-303 pubmed publisher..We conclude that sunitinib might ameliorate Tat-mediated autophagy alterations and may decrease neurodegeneration in aging patients with HAND. ..
- FIELDS J, Dumaop W, Crews L, Adame A, Spencer B, Metcalf J, et al. Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders. Curr HIV Res. 2015;13:43-54 pubmed..g.: Tau, CRMP2, DCX] that impair neuronal function and eventually lead to cell death. Novel therapeutic approaches with compounds that block Tat mediated hyper-activation of CDK5 might be of value in the management of HAND. ..
- Fields J, Dumaop W, Eleuteri S, Elueteri S, Campos S, Serger E, et al. HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders. J Neurosci. 2015;35:1921-38 pubmed publisher..Therapies targeting Tat-mediated autophagy alterations may decrease neurodegeneration in aging patients with HAND. ..
- Crews L, Ruf R, Patrick C, Dumaop W, Trejo Morales M, Achim C, et al. Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders. Mol Neurodegener. 2011;6:67 pubmed publisher..We have developed an in vitro model of abnormal CDK5 activation during adult hippocampal neurogenesis, and here we used this model to investigate aberrantly phosphorylated downstream targets of CDK5...
- Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE. 2011;6:e19338 pubmed publisher..These results suggest that passive immunization with monoclonal antibodies against the CT of ?-syn may be of therapeutic relevance in patients with PD and DLB...
- Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98:12245-50 pubmed..Therefore, treatments that block the production or accumulation of beta-amyloid peptides could benefit a broader spectrum of disorders than previously anticipated. ..